Massachusetts Financial Services’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $717M | Buy |
10,996,572
+1,911,044
| +21% | +$153M | 0.24% | 109 |
|
|
2025
Q4 | $866M | Sell |
9,085,528
-1,281,765
| -12% | -$126M | 0.28% | 97 |
|
|
2025
Q3 | $1.01B | Sell |
10,367,293
-2,491,865
| -19% | -$258M | 0.31% | 90 |
|
|
2025
Q2 | $1.38B | Sell |
12,859,158
-3,662,461
| -22% | -$371M | 0.44% | 65 |
|
|
2025
Q1 | $1.67B | Sell |
16,521,619
-3,138,336
| -16% | -$316M | 0.55% | 50 |
|
|
2024
Q4 | $1.76B | Sell |
19,659,955
-6,007,738
| -23% | -$529M | 0.55% | 43 |
|
|
2024
Q3 | $2.15B | Sell |
25,667,693
-6,117,525
| -19% | -$482M | 0.64% | 33 |
|
|
2024
Q2 | $2.45B | Sell |
31,785,218
-14,821,798
| -32% | -$1.08B | 0.75% | 24 |
|
|
2024
Q1 | $3.19B | Sell |
46,607,016
-10,568,954
| -18% | -$680M | 0.95% | 17 |
|
|
2023
Q4 | $3.31B | Sell |
57,175,970
-5,357,412
| -9% | -$286M | 1.07% | 13 |
|
|
2023
Q3 | $3.3B | Sell |
62,533,382
-6,603,703
| -10% | -$346M | 1.16% | 14 |
|
|
2023
Q2 | $3.74B | Sell |
69,137,085
-10,396,546
| -13% | -$543M | 1.23% | 11 |
|
|
2023
Q1 | $3.98B | Sell |
79,533,631
-2,450,247
| -3% | -$115M | 1.36% | 10 |
|
|
2022
Q4 | $3.79B | Sell |
81,983,878
-2,107,674
| -3% | -$91.3M | 1.32% | 10 |
|
|
2022
Q3 | $3.26B | Buy |
84,091,552
+485,936
| +0.6% | +$19.5M | 1.22% | 11 |
|
|
2022
Q2 | $3.12B | Sell |
83,605,616
-563,369
| -0.7% | -$22.9M | 1.07% | 16 |
|
|
2022
Q1 | $3.73B | Sell |
84,168,985
-1,365,490
| -2% | -$59.2M | 1.1% | 15 |
|
|
2021
Q4 | $3.63B | Buy |
85,534,475
+1,738,853
| +2% | +$73.1M | 0.99% | 18 |
|
|
2021
Q3 | $3.64B | Sell |
83,795,622
-627,678
| -0.7% | -$27.8M | 1.06% | 17 |
|
|
2021
Q2 | $3.61B | Buy |
84,423,300
+1,763,829
| +2% | +$74.2M | 1.05% | 18 |
|
|
2021
Q1 | $3.19B | Buy |
82,659,471
+33,630,705
| +69% | +$1.27B | 0.98% | 20 |
|
|
2020
Q4 | $1.76B | Buy |
49,028,766
+5,703,310
| +13% | +$206M | 0.57% | 47 |
|
|
2020
Q3 | $1.66B | Buy |
43,325,456
+306,813
| +0.7% | +$11.8M | 0.6% | 40 |
|
|
2020
Q2 | $1.51B | Buy |
43,018,643
+13,284,649
| +45% | +$478M | 0.6% | 42 |
|
|
2020
Q1 | $970M | Buy |
29,733,994
+16,151,261
| +119% | +$631M | 0.46% | 63 |
|
|
2019
Q4 | $614M | Buy |
13,582,733
+1,354,675
| +11% | +$56.7M | 0.23% | 108 |
|
|
2019
Q3 | $498M | Buy |
12,228,058
+623,179
| +5% | +$26.4M | 0.2% | 122 |
|
|
2019
Q2 | $499M | Buy |
11,604,879
+220,156
| +2% | +$8.47M | 0.2% | 119 |
|
|
2019
Q1 | $437M | Buy |
11,384,723
+3,439,762
| +43% | +$131M | 0.18% | 126 |
|
|
2018
Q4 | $281M | Buy |
7,944,961
+4,941,897
| +165% | +$179M | 0.13% | 153 |
|
|
2018
Q3 | $116M | Buy |
+3,003,064
| New | +$105M | 0.05% | 264 |
|
|
2015
Q2 | – | Sell |
-1,042,321
| Closed | -$18.5M | – | 888 |
|
|
2015
Q1 | $18.5M | Buy |
+1,042,321
| New | +$16.5M | 0.01% | 545 |
|
Other funds holding BSX
VCM
VPM
Massachusetts Financial Services's BSX Position: Q1 2026 in Review
Massachusetts Financial Services increased its Boston Scientific (BSX) stake by 21% in Q1 2026, buying an estimated $153M and bringing the position to 10,996,572 shares worth $717M. The position accounts for 0.24% of the portfolio, ranked #109.
Massachusetts Financial Services first reported a position in BSX in Q1 2015 and has held it in 32 quarters since. The position peaked at $3.98B in Q1 2023. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Massachusetts Financial Services held 10,996,572 shares of Boston Scientific worth $717M as of Q1 2026.
- Massachusetts Financial Services bought 1,911,044 Boston Scientific shares in Q1 2026, an estimated $153M.
- Boston Scientific made up 0.24% of Massachusetts Financial Services's portfolio in Q1 2026, its #109 holding.
- Massachusetts Financial Services first reported a position in Boston Scientific in Q1 2015 and has held it in 32 quarters since.
- Massachusetts Financial Services's Boston Scientific position peaked at $3.98B in Q1 2023.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Massachusetts Financial Services's 13F filing for Q1 2026, filed 14 May 2026.